MR波谱测量的肌醇水平有助于预测复发性胶质母细胞瘤抗血管生成治疗失败
这项前瞻性纵向研究(2016-2020年)对21例接受贝伐珠单抗治疗的复发性胶质母细胞瘤患者,在基线及治疗后1天、4周、8周进行MR波谱成像,测量肿瘤内、对侧正常表现组织和瘤周体积中经对侧肌酸校正的肌醇水平。结果显示,较低水平的校正肌醇可预测较差的生存期和治疗失败,且早在贝伐珠单抗治疗前即可预测。
要点
- 肿瘤内校正肌醇较低(基线、治疗后1天、8周)预测抗血管生成治疗失败和生存期缩短。
- 对侧正常表现组织和瘤周体积中校正肌醇较低也与较短生存期相关。
- MR波谱成像可补充常规MRI,提供肿瘤生物学信息以辅助治疗决策。
局限性
- 样本量较小(21例),单中心研究。
- 部分时间点AUC值基于小样本,需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Patients with recurrent glioblastoma (GBM) are often treated with antiangiogenic agents, such as bevacizumab (BEV). Despite therapeutic promise, conventional MRI methods fail to help determine which patients may not benefit from this treatment. Purpose To use MR spectroscopic imaging (MRSI) with intermediate and short echo time to measure corrected myo-inositol (mI)normalized by contralateral creatine (hereafter, mI/c-Cr) in participants with recurrent GBM treated with BEV and to investigate whether such measurements can help predict survivorship before BEV initiation (baseline) and at 1 day, 4 weeks, and 8 weeks thereafter. Materials and Methods In this prospective longitudinal study (2016-2020), spectroscopic data on mI-a glial marker and osmoregulator within the brain-normalized by contralateral creatine in the intratumoral, contralateral, and peritumoral volumes of patients with recurrent GBM were evaluated. Area under the receiver operating characteristic curve (AUC) was calculated for all volumes at baseline and 1 day, 4 weeks, and 8 weeks after treatment to determine the ability of mI/c-Cr to help predict survivorship. Results Twenty-one participants (median age ± standard deviation, 62 years ± 12; 15 men) were evaluated. Lower mI/c-Cr in the tumor before and during BEV treatment was predictive of poor survivorship, with receiver operating characteristic analyses showing an AUC of 0.75 at baseline, 0.87 at 1 day after treatment, and 1 at 8 weeks after. A similar result was observed in contralateral normal-appearing tissue and the peritumoral volume, with shorter-term survivors having lower levels of mI/c-Cr. In the contralateral volume, a lower ratio of mI to creatine (hereafter, mI/Cr) predicted shorter-term survival at baseline and all other time points. Within the peritumoral volume, lower mI/c-Cr levels were predictive of shorter-term survival at baseline (AUC, 0.80), at 1 day after treatment (AUC, 0.93), and at 4 weeks after treatment (AUC, 0.68). Conclusion Lower levels of myo-inositol normalized by contralateral creatine within intratumoral, contralateral, and peritumoral volumes were predictive of poor survivorship and antiangiogenic treatment failure as early as before bevacizumab treatment. Adapting MR spectroscopic imaging alongside conventional MRI modalities conveys critical information regarding the biologic characteristics of tumors to help better treat individuals with recurrent glioblastoma. Clinical trial registration no. NCT02843230 © RSNA, 2021 Online supplemental material is available for this article.
引用
- El-Abtah, Wenke, Talati, et al. Myo-Inositol Levels Measured with MR Spectroscopy Can Help Predict Failure of Antiangiogenic Treatment in Recurrent Glioblastoma. Radiology. 2021. PMID: 34751617. doi:10.1148/radiol.2021210826
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。